Lucky boy, the purchase agreement of 13 products with capacity in Shanghai will be renewed for one year

On August 19, Shanghai Yangguang pharmaceutical purchase network published the notice on renewal of purchase agreement of winning bid drugs in volume purchase, which combed and elaborated the follow-up problems of volume purchase: medical insurance bureaus, health and health committees in each district, designated medical institutions in each medical insurance, and relevant pharmaceutical production and marketing enterprises: Shanghai Municipality has executed the bid winning result of the third batch of medical insurance drug volume purchase (Document No.: sh-dl2017-1) of Shanghai medical institutions since September 1, 2018 During the procurement period, the performance is good, the quality of the winning drugs is stable, the supply is sufficient, and the clinical use is stable At present, part of the winning drugs have completed the contract procurement volume and the procurement period is about to end With the consent of the superior competent department, the bid winning enterprise and its drug purchase agreement shall be renewed for one year: the bid winning drug has passed the quality and efficacy consistency evaluation of generic drugs (hereinafter referred to as consistency evaluation), and the bid winning drug enterprise agrees to continue to supply with the bid price; The bid winning drug fails to pass the consistency evaluation, other manufacturers with the same generic name and specification fail to pass the consistency evaluation, and the bid winning drug enterprise agrees to continue to supply with the bid price; If the winning drugs fail to pass the consistency evaluation, there are less than 3 original research and consistency evaluation drug enterprises with the same generic name and specification, and the original research and consistency evaluation drug enterprises with the same product specification are inquired with the bidding price, and the consistency evaluation drug enterprises are not responsive It also released the information about the manufacturers and bid prices of the 13 products under the renewed contract, and pointed out that the agreement will last until August 31, 2020 In fact, the most important thing for the renewal enterprise is the overall volume of next year If the total volume of each second year is higher than that of the previous year, the overall effect of price for volume will be far greater than that of the previous year Therefore, quantity is the key In addition, there are four products that need to be purchased intensively in 2020, and each manufacturer can fill in the application according to the requirements: in the same period, Hanhui Pharmaceutical Co., Ltd will replace simvastatin produced by the former bid winning enterprise sanders (China) Pharmaceutical Co., Ltd to supply in the whole city from December 1, 2019 Attachment: centralized drug volume purchase document of Shanghai Doc this article is the content reprinted by yaozhi.com, and the copyright belongs to the original author The purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.